• 1
    Canellos GP,Anderson JR,Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992; 327: 14781484.
  • 2
    Duggan DB,Petroni GR,Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003; 21: 607614.
  • 3
    Gobbi PG,Levis A,Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005; 23: 91989207.
  • 4
    Canellos GP. Is there an effective salvage therapy for advanced Hodgkin's disease? Ann Oncol. 1991; 2( suppl 1): 17.
  • 5
    Longo DL,Duffey PL,Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992; 10: 210218.
  • 6
    Canellos GP,Petroni GR,Barcos M, et al. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B. J Clin Oncol. 1995; 13: 20052011.
  • 7
    Ferme C,Bastion Y,Lepage E, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol. 1995; 6: 543549.
  • 8
    Tourani JM,Levy R,Colonna P, et al. High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease. J Clin Oncol. 1992; 10: 10861094.
  • 9
    Linch DC,Winfield D,Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993; 341: 10511054.
  • 10
    Schmitz N,Glass B,Dreger P, et al. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease. Ann Hematol. 1993; 66: 251256.
  • 11
    Colwill R,Crump M,Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol. 1995; 13: 396402.
  • 12
    Vigouroux S,Milpied N,Andrieu JM, et al. Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy. Bone Marrow Transplant. 2002; 29: 833842.
  • 13
    Carbone PP,Kaplan HS,Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971; 31: 18601861.
  • 14
    Hasenclever D,Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998; 339: 15061514.
  • 15
    Federico M,Bellei M,Brice P, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol. 2003; 21: 23202325.
  • 16
    Horning SJ,Hoppe RT,Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002; 20: 630637.
  • 17
    Diehl V,Franklin J,Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003; 348: 23862395.
  • 18
    Behringer K,Diehl V. Twenty-five years clinical trials of the German Hodgkin Study Group (GHSG). Eur J Haematol. 2005; 75( suppl): 2125.
  • 19
    Gianni AM,Rambaldi A,Zinzani P, et al. Comparable 3-year outcome after ABVD or BEACOPP first-line chemotherapy, plus preplanned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomized trial of the Michelangelo, GITIL and HL cooperative groups [abstract]. J Clin Oncol. 2008; 26S. Abstract 8506.
  • 20
    Bonadonna G,Zucali R,Monfardini S,De Lena M,Uslenghi C. Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975; 36: 252259.
  • 21
    Horning SJ. Risk, cure and complications in advanced Hodgkin disease. Hematol Am Soc Hematol Educ Program. 2007; 2007: 197203.